Abstract
Ovarian cancer (OC) has the worst prognosis among gynecological malignancies. Cisplatin (CDDP) is one of the most commonly used treatments for OC, but recurrence and metastasis are common due to endogenous or acquired resistance. High expression of ATP-binding cassette (ABC) transporters is an important mechanism of resistance to OC chemotherapy, but targeting ABC transporters in OC therapy remains a challenge. The expression of sortilin-related receptor 1 (SORL1; SorLA) in the response of OC to CDDP was determined by analysis of TCGA and GEO public datasets. Immunohistochemistry and western blotting were utilized to evaluate the expression levels of SORL1 in OC tissues and cells that were sensitive or resistant to CDDP treatment. The in vitro effect of SORL1 on OC cisplatin resistance was proven by CCK-8 and cell apoptosis assays. The subcutaneous xenotransplantation model verified the in vivo significance of SORL1 in OC. Finally, the molecular mechanism by which SORL1 regulates OC cisplatin resistance was revealed by coimmunoprecipitation, gene set enrichment analysis and immunofluorescence analysis. This study demonstrated that SORL1 is closely related to CDDP resistance and predicts a poor prognosis in OC. In vivo xenograft experiments showed that SORL1 knockdown significantly enhanced the effect of CDDP on CDDP-resistant OC cells. Mechanistically, silencing of SORL1 inhibits the early endosomal antigen 1 (EEA1) pathway, which impedes the stability of ATP-binding cassette B subfamily member 1 (ABCB1), sensitizing CDDP-resistant OC cells to CDDP. The findings of this study suggest that targeting SORL1 may represent a promising therapeutic approach for overcoming CDDP resistance in OC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data are publicly available.
References
Al-Akhrass H, Conway JRW, Poulsen ASA, Paatero I, Kaivola J, Padzik A, Andersen OM, Jl I (2021) A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. Oncogene 40:1300–1317
Bamidele AO, Kremer KN, Hirsova P, Clift IC, Gores GJ, Billadeau DD, KEl H (2015) IQGAP1 promotes CXCR4 chemokine receptor function and trafficking via EEA-1+ endosomes. J Cell Biol 210:257–272
Campion D, Charbonnier C, Gl N (2019) SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol 138:173–186
Cheng M, Cai W, Huang W, Chen Y, Wu Z, Luo P, Wl Y (2018) Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription. Eur J Pharmacol 840:1–8
Christie EL, DDLl B (2017) Acquired chemotherapy resistance in ovarian cancer. Ann Oncol 28:viii13–vviii5
Dai M, Yang B, Chen J, Liu F, Zhou Y, Zhou Y, Xu Q, Jiang S, Zhao S, Li X, Zhou X, Yang Q, Li J, Wang Y, Zhang Z, Yl T (2021) Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer. Cancer Lett 513:36–49
Damia G, Ml B (2019) Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers (Basel) 11:119
Fraser J, Simpson J, Fontana R, Kishi-Itakura C, Ktistakis NT, Nl G (2019) Targeting of early endosomes by autophagy facilitates EGFR recycling and signalling. EMBO Rep 20:e47734
Fu D, IMl A (2012) Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol 44:461–464
Hu LP, Huang W, Wang X, Xu C, Qin WT, Li D, Tian G, Li Q, Zhou Y, Chen S, Nie HZ, Hao Y, Song J, Zhang XL, Sundquist J, Sundquist K, Li J, Jiang SH, Zhang ZG, Jl J (2022) Terbinafine prevents colorectal cancer growth by inducing dNTP starvation and reducing immune suppression. Mol Ther 30:3284–3299
Huo Y, Yang J, Zheng J, Xu D, Yang M, Tao L, Yao H, Fu X, Yang J, Liu D, Hua R, Zhang J, Sun Y, Hu L, Wl L (2022) Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Cell Prolif 55:e13237
Jiang SH, Zhu LL, Zhang M, Li RK, Yang Q, Yan JY, Zhang C, Yang JY, Dong FY, Dai M, Hu LP, Li J, Li Q, Wang YH, Yang XM, Zhang YL, Nie HZ, Zhu L, Zhang XL, Tian GA, Zhang XX, Cao XY, Tao LY, Huang S, Jiang YS, Hua R, Qian Luo K, Gu JR, Sun YW, Hou S, Zhang ZGl (2019) GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut 68:1994–2006
Katayama K, Kapoor K, Ohnuma S, Patel A, Swaim W, Ambudkar IS, SVl A (2015) Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. Biochim Biophys Acta 1853:2361–2370
Kim JY, Bahar E, Lee JY, Chang S, Kim SH, Park EY, Do SI, Yoon H, HSl K (2022) ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma. Cell Death Dis 13:239
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, CMl A (2020) Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 38:1222–1245
Lheureux S, Braunstein M, AMl O (2019) Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 69:280–304
Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, ZSl C (2016) Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resist Updat 27:14–29
Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G, Al F (2021) Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin Cancer Biol 77:144–166
Pietila EA, Gonzalez-Molina J, Moyano-Galceran L, Jamalzadeh S, Zhang K, Lehtinen L, Turunen SP, Martins TA, Gultekin O, Lamminen T, Kaipio K, Joneborg U, Hynninen J, Hietanen S, Grenman S, Lehtonen R, Hautaniemi S, Carpen O, Carlson JW, Kl L (2021) Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat Commun 12:3904
Pietila M, Sahgal P, Peuhu E, Jantti NZ, Paatero I, Narva E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Bostrom PJ, Taimen P, Jl I (2019) SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun 10:2340
Pokharel D, Roseblade A, Oenarto V, Lu JF, Ml B (2017) Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. Ecancermedicalscience 11:768
Schmidt V, Subkhangulova A, TEl W (2017) Sorting receptor SORLA: cellular mechanisms and implications for disease. Cell Mol Life Sci 74:1475–1483
Siegel RL, Miller KD, Fuchs HE, Al J (2021) Cancer Statistics, 2021. CA Cancer J Clin 71:7–33
Siegel RL, Miller KD, Fuchs HE, Al J (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33
Stupack J, Xiong XP, Jiang LL, Zhang T, Zhou L, Campos A, Ranscht B, Mobley W, Pasquale EB, Xu H, TYl H (2020) Soluble SORLA Enhances Neurite Outgrowth and Regeneration through Activation of the EGF Receptor/ERK Signaling Axis. J Neurosci 40:5908–5921
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Fl B (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249
Talbot H, Saada S, Naves T, Gallet PF, Fauchais AL, MOl J (2018) Regulatory Roles of Sortilin and SorLA in Immune-Related Processes. Front Pharmacol 9:1507
Wu KKL, Cheng KKY (2022) A new role of the early endosome in restricting NLRP3 inflammasome via mitophagy. Autophagy 18:1475–1477
Xie Y, Burcu M, Linn DE, Qiu Y, MRl B (2010) Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol Pharmacol 78:310–318
Yan YY, Wang F, Zhao XQ, Wang XK, Chen YF, Liu H, Xie Y, LWl F (2017) Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro. Oncol Rep 37:31–40
Yang B, Chen J, Li X, Zhang X, Hu L, Jiang S, Zhang Z, Yl T (2021) TNPO1-mediated nuclear import of ARID1B promotes tumor growth in ARID1A-deficient gynecologic cancer. Cancer Lett 515:14–27
Zhou Y, Liu F, Xu Q, Yang B, Li X, Jiang S, Hu L, Zhang X, Zhu L, Li Q, Zhu X, Shao H, Dai M, Shen Y, Ni B, Wang S, Zhang Z, Yl T (2020) Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer. Oncogene 39:5633–5648
Funding
This research was supported by the National Natural Science Foundation of China (No. 81974406, No. 82002730 and No.82172934).
Author information
Authors and Affiliations
Contributions
ZZ, Y-CT, and LP-H devised the study's concept and design. XL partnered with B-KY to assemble the database. Q-YX collaborated with X-LZ on statistical analysis. The initial manuscript draft was authored by ZZ, Y-CT, and LP-H. XL and B-KY composed various manuscript sections. All authors participated in revising, reviewing, and approving the final submission.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
ESM 1
(DOCX 671 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zheng, Z., Li, X., Yang, B. et al. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer. Funct Integr Genomics 23, 147 (2023). https://doi.org/10.1007/s10142-023-01075-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10142-023-01075-3